Q-omics provides the consensus-scored RIPPLY1 profile across patient tissues and cancer cell-line models. RIPPLY1 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RIPPLY1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RIPPLY1 RNA expression shows 13,070 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, KIRC, and TGCT as cancer lineages where RIPPLY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPPLY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPPLY1 survival associations across molecular data types. RIPPLY1 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPPLY1 RNA expression–survival associations across cancer types. High RIPPLY1 expression shows unfavorable associations in LAML, DLBC and HNSC, but favorable associations in THCA, UCS and LIHC. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for RIPPLY1 RNA expression.
This table summarizes RIPPLY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RIPPLY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPPLY1 shows lower tumor expression in KIRC, KICH, CHOL, KIRP and BRCA and higher tumor expression in COAD. The KIRC box plot shows higher RIPPLY1 RNA expression in normal versus tumor tissue (log2 FC = −2.203, t-test p < 0.001).
This table shows molecular features associated with RIPPLY1 in patient tissues and cancer cell lines. In patient samples, RIPPLY1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPPLY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
